Previous studies revealed that phenylhistamines and histaprodifens possess higher potency and affinity at guinea pig histamine H 1 -receptor (gpH 1 R) than at human histamine H 1 -receptor (hH 1 R). However, we recently identified an imidazolylpropyl-
histamine moiety showed a high flexibility in the binding pocket. There are striking similarities in ligand properties in bulky phenylhistamines and UR-AK57. Comparison of bulky phenylhistamine binding mode with binding mode of UR-AK57 suggests that only one of these four binding modes should be established. The higher potency is explained by more effective van der Waals interaction of the compounds with Asn 2.61 (hH 1 R) relative to Ser 2.61 (gpH 1 R). In addition, two stable binding modes for phenoprodifens with different orientations in the binding-pocket were identified. Depending on phenoprodifen orientation, the highly conserved Trp 6.48 , part of the toggle switch involved in receptor activation, was found in an inactive or active conformation, respectively. We identified the first phenylhistamines with higher potency at hH 1 R than at gpH 1 R and obtained insight into the binding mode of bulky phenylhistamines and imidazolylpropylguanidines.
The biogenic amine histamine binds to, and activates, histamine receptors. Histamine mediates a variety of physiological and pathophysiological effects. All histamine receptors belong to the rhodopsin-like G-protein-coupled receptors (GPCRs). Meanwhile, four histamine receptor subtypes have been cloned: the histamine H 1 receptor (H 1 R) (Moguilevsky et al., 1994) , the histamine H 2 receptor (H 2 R) (Gantz et al., 1991) , the histamine H 3 receptor (H 3 R) (Lovenberg et al., 1999) and the histamine H 4 receptor (H 4 R) (Oda et al., 2000) . The H 1 R interacts with G q -proteins to activate phospholipase C (Hill et al., 1997) . H 1 R antagonists, divided into first-and second-generation antagonists, are used therapeutically, whereas H 1 R agonists are important tools to study the pharmacology of the H 1 R at the molecular level. Different classes of H 1 R agonists are known, including small agonists derived from histamine (1 in Fig. 1 ) and bulkier agonists such as phenylhistamines (2, 4, and 6 in Fig. 1 ) Zingel et al., 1995) , ergolines (Pertz et al., 2006) , and histaprodifens (12 and 17 in Fig. 1 ) (Elz et al., 2000; Menghin et al., 2003) . In addition, imidazolypropylguanidines, originally designed as selective H 2 R agonists, act as partial H 1 R agonists, too (Xie et al., 2006) . In fact, the imidazolylpropylguanidine UR-AK57 (19 in Fig. 1 ) (Xie et al., 2006) is the first synthetic agonist that shows higher potency at hH 1 R than at gpH 1 R. Asn 2.61 acts as a selectivity switch between hH 1 R and gpH 1 R for suprahistaprodifen (Menghin et al., 2003) . Our recent study with histaprodifens at hH 1 R and gpH 1 R corroborated the fact that Asn 2.61 acts as selectivity switch (Straßer et al., 2008b) .
Several phenylhistamines and histaprodifens , as well as ergolines (Pertz et al., 2006) , were studied at the recombinant guinea pig H 1 -receptor (gpH 1 R) and human H 1 -receptor (hH 1 R) expressed in Sf9 insect cell membranes by [ 3 H]mepyramine competition binding and G qprotein-catalyzed GTP hydrolysis. In general, the affinity of phenylhistamines and histaprodifens is higher at gpH 1 R than at hH 1 R . Because a more recent study revealed species differences for histaprodifens between hH 1 R, bovine H 1 -receptor (bH 1 R), rat H 1 -receptor (rH 1 R), and gpH 1 R (Straßer et al., 2008a) , we also expect species differences in pharmacology for members of several subclasses of phenylhistamines: 1) small phenylhistamines ( Fig.  1, 2-6 ), 2) bulky phenylhistamines with an additional histamine moiety (Fig. 1, 7-9 ), 3) dimeric phenylhistamines (Fig.  1, 10 and 11) , and 4) phenoprodifens (phenylhistamines coupled to a histaprodifen partial structure) (Fig. 1, 13-16) . To study the H 1 R-species-dependent pharmacology of these compounds, we coexpressed hH 1 R, bH 1 R, rH 1 R, or gpH 1 R with the regulator of G-protein signaling RGS4 in Sf9 insect cells and characterized known and 11 novel phenylhistamines and phenoprodifens ( Fig. 1) in [ 3 H]mepyramine competition binding and GTPase assays. The pharmacological analysis of synthetic ligands, not only at hH 1 R, but also at bH 1 R, rH 1 R and gpH 1 R, is a standard technique, taking advantage of the differences in amino acid sequence between H 1 R species isoforms as natural mutations (Straßer et al., 2008a) . This technique allows us to obtain useful information about the interactions of amino acids with the ligand in the binding pocket. Beyond the H 1 R, the analysis of receptor species isoforms has also been most valuable for the H 2 R (Preuss et al., 2007a) , H 3 R (Ligneau et al., 2000) , and H 4 R (Thurmond et al., 2004) .
To obtain information about the binding mode of bulky phenylhistamines and phenoprodifens, we docked these compounds into active state models of gpH 1 R and hH 1 R (Straßer Fig. 1 . Structures of histamine, phenylhistamines, phenoprodifens, mepyramine, and imidazolylpropylguanidine UR-AK57. Histamine 1, small phenylhistamines 2-6, bulky phenylhistamines with an additional histamine moiety 7 to 9, dimeric phenylhistamines 10 and 11, histaprodifen 12, phenoprodifens 13 to 16, dimeric histaprodifen 17, mepyramine 18, and imidazolylpropylguanidine 19 (UR-AK57). et al., 2008a,b) and performed molecular dynamics (MD) simulations, including the surrounding of the receptor.
Materials and Methods

Materials. [␥-
32 P]GTP was synthesized as described previously (Preuss et al., 2007b) . [ 3 H]Mepyramine (30.0 Ci/mmol) was from PerkinElmer Life and Analytical Sciences (Walatham, MA). Rotiszint Eco Plus from Roth (Karlsruhe, Germany) was used as liquid scintillation cocktail. Phenylhistamines and phenoprodifens were synthesized as described previously (Kunze, 2006) . Sources of all other materials were described previously Straßer et al., 2008a,b) .
Preparation of Compound Stock Solutions. Chemical structures of the analyzed compounds are given in Fig. 1 . Compounds 2 to 9 (10 mM each) were dissolved in double-distilled water. Compounds 10, 11, 15, and 16 (5 mM each) were dissolved in a solvent containing 50% (v/v) DMSO and 50% (v/v) double-distilled water. All other ligands were dissolved as described previously (Straßer et al., 2008a) . The final DMSO concentration in all assays was adjusted to 5% (v/v) as appropriate for the ligands 10, 11, 15, and 16. Control experiments with histamine, dissolved in double-distilled water or dissolved in a solvent containing 50% (v/v) DMSO and 50% (v/v) double-distilled water, showed that a final DMSO concentration of 5% (v/v) did not shift pK i and pEC 50 values of histamine.
Pharmacological and Biochemical Methods. Construction of baculoviruses was described previously (Kelley et al., 2001; Straßer et al., 2008a) . Cell culture, membrane preparation and determination of protein concentration were performed as described previously Straßer et al., 2008a) . [ 3 H]Mepyramine competition binding assay and steady-state GTPase assay were performed as described previously (Kelley et al., 2001; Straßer et al., 2008a) . All assays for comparison of pharmacological data were carried out under the same experimental conditions and in parallel. For data analysis the software Prism 4.02 (GraphPad Software Inc., San Diego, CA) was used. pK i and pK B values were calculated according to Cheng and Prusoff (1973) . All data are the means Ϯ S.E.M. of at least three independent experiments. For comparison of two pairs of data, the significance of the deviation of zero p was calculated using the t test.
Construction of Active H 1 R Models with Phenoprodifen 13, Phenylhistamine 9, and Imidazolypropylguanidine 19 in the Binding Pocket. The active state gpH 1 R and hH 1 R homology models were developed on the basis of the new crystal structure of the human ␤ 2 -adrenergic receptor (h␤ 2 AR) Rasmussen et al., 2007; Rosenbaum et al., 2007) . Both models were constructed as described previously (Straßer et al., 2008b ) using restrained molecular dynamics simulations and considering experimental data of activated GPCRs (Niv et al., 2006) . Based on the active state models of H 1 Rs, ligands 9, 13, and 19 were docked manually, and further MD simulations were carried out. The equilibration phase and the productive phase were performed as described previously (Straßer et al., 2008a) . For all MD simulations, the software package GROMACS 3.3.1 (http://www.gromacs.org/) was used in combination with the ffG53A6 force field (Oostenbrink et al., 2004) . The force field parameters for the bromine-substituted phenylhistamine 9, phenoprodifen 13, and imidazolylpropylguanidine 19 were adopted from the ffG53A6 force field. The electrostatic potential surface was calculated with Sybyl 7.0 (Tripos, St. Louis, MO) based on Gasteiger-Hü ckel partial charges. For multifit alignment of phenylhistamine 9 and imidazolylpropylguanidine 19, Sybyl 7.0 was used.
Model to Predict the Orientation of the Unsubstituted Phenoprodifen 13. To analyze the question of orientation of the unsubstituted phenoprodifen 13, we implemented the model illustrated in Fig. 2 . The dimeric phenylhistamine 10 and dimeric histaprodifen 17 were divided into the parts PheHIS-1, PheHIS-2, HP-1, and HP-2, respectively ( Fig. 2A) . The moieties PheHIS-1 and HP-1 were related to the phenylhistamine 2 and histaprodifen 12, respectively, with regard to their pK i values, which represent the log 10 of the association constants of the receptor-ligand-complexes. The ⌬pK i values of the moieties PheHIS-2 and HP-2 (Fig. 2B) were calculated by pK i (10) Ϫ pK i (2) and pK i (17) Ϫ pK i (12). Subsequently, the pK i value of the phenoprodifen 13 was calculated by pK i (orientation 1) ϭ pK i (12) ϩ ⌬pK i (PheHIS-2) in case of orientation 1 and by pK i (orientation 2) ϭ pK i (2) ϩ ⌬pK i (HP-2) in case of orientation 2. The term 10 pKi(orientation 1) /10 pKi(orientation 2) corresponds to the ratio concentration (orientation 1)/concentration (orientation 2). For calculation of pK i values, including orientation 1 and orientation 2, the equation log 10 [K i (orientation 1) ϩ K i (orientation 2)] was used.
Results
Analysis of Phenylhistamines and Phenoprodifens at H 1 R Species Isoforms in the [
3 H]Mepyramine Competition Binding Assay. The affinities of the compounds determined in the competition binding assay are given in Table 1 . At hH 1 R and bH 1 R, the affinity of phenylhistamine 2 was lower than for histamine 1, but at rH 1 R and gpH 1 R, the affinity for 2 was in the same range as for 1. The introduction of an additional methyl group in phenylhistamines in S-configuration (3S) showed no significant difference compared with the unmethylated compound 2. However, a significant decrease in pK i values was observed for compound 3R with the additional methyl group in R-configuration. The introduction of a trifluoromethyl group in meta position into the phenyl moiety of the phenylhistamine 4 led to an increase of approximately 0.5-0.7 in pK i values compared with the unsubstituted phenylhistamine 2 at all four species isoforms. The S-enantiomer 5S showed the same affinity as the unmethylated derivative 4 at hH 1 R, bH 1 R, rH 1 R and gpH 1 R. However, there was a significant decrease (p Ͻ 0.001 at hH 1 R and bH 1 R, p Ͻ 0.01 at rH 1 R, p Ͻ 0.0001 at gpH 1 R) of approximately 1 unit in pK i of the R-enantiomer 5R compared with the S-enantiomer 5S at all four species isoforms. The exchange of the trifluoromethyl group to bromine 6 did not reveal significant differences in affinities of 6 compared with 4 at hH 1 R, bH 1 R, rH 1 R, and gpH 1 R.
The affinities of phenylhistamine 7 showed no significant differences at hH 1 R, bH 1 R, and rH 1 R, but at gpH 1 R, the pK i of 7 was significantly lower than of 2 (p Ͻ 0.05). There was no significant difference in affinities of 7 among all four species isoforms. The pK i values of the bulky trifluoromethylated phenylhistamine 8 compared with the small trifluoromethylated phenylhistamine 4 showed a significant decrease at gpH 1 R (p Ͻ 0.001). The affinities of 8 at hH 1 R and rH 1 R on the one hand and at bH 1 R and gpH 1 R on the other hand were not significantly different from one another, but the affinities of 8 were significantly higher at hH 1 R and rH 1 R compared with bH 1 R and gpH 1 R (p Ͻ 0.0002). The pK i values of the bromine-substituted bulky phenylhistamine 9 compared with the bromine-substituted phenylhistamine 6 showed a significant increase at hH 1 R (p Ͻ 0.02), no significant difference at bH 1 R and rH 1 R, but a significant decrease at gpH 1 R (p Ͻ 0.02). The affinities of 9 (Fig. 3A) at hH 1 R and rH 1 R on the one hand and at bH 1 R and gpH 1 R on the other hand were not significantly different from one another, but the affinities of 9 were higher at hH 1 R and rH 1 R compared with bH 1 R and gpH 1 R.
The affinities of the dimeric phenylhistamine 10 were in the same range as for the monomeric phenylhistamine 2 at all four species isoforms. The trifluoromethylated phenylhistamine 11 showed affinities comparable with those of 10.
The introduction of an additional methyl group into phenoprodifen 13 led to the chiral phenoprodifens 14R and 14S showing lower affinities than 13 at all four species isoforms (Straßer et al., 2008a) . The trifluoromethyl-substituted (15) and bromine-substituted (16) phenoprodifens showed a decrease in affinity at all four species isoforms, compared with the unsubstituted phenoprodifen 13. Moreover, the affinities of 15 and 16 increased in the series bH 1 R Ͻ hH 1 R Ͻ rH 1 R Ͻ gpH 1 R. The affinities of dimeric histaprodifen 17 were in a range comparable to that found for phenoprodifen 13 or slightly higher.
Analysis of Phenylhistamines and Phenoprodifens at H 1 R Species Isoforms in the Steady-State GTPase Assay. The potencies and efficacies of phenylhistamines and phenoprodifens determined in the steady-state GTPase assay are given in Table 2 . Compared with histamine 1, phenylhistamine 2 showed a significantly lower potency at hH 1 R and bH 1 R, but at rH 1 R and gpH 1 R, the potencies of 2 and 1 were TABLE 1 Affinities of histamine, phenylhistamines, and phenoprodifens at hH 1 R, bH 1 R, rH 1 R, and gpH 1 R coexpressed with RGS4 in Sf9 cell membranes in the competition binding assay ͓ 3 H͔Mepyramine competition binding in Sf9 membranes expressing hH 1 R, bH 1 R, rH 1 R, and gpH 1 R in combination with RGS4 was determined in presence of 5 nM ͓ 3 H͔mepyramine as described under Materials and Methods. Data were analyzed by nonlinear regression and were best fit to one-site (monophasic) competition curves. pK i values were calculated according to Cheng and Prusoff (1973) . Data shown are the means Ϯ S.E.M. of at least three experiments with independent membrane preparations each performed in duplicate. in a comparable range. The efficacy of phenylhistamine 2 increased in the series hH 1 R Ͻ bH 1 R Ͻ rH 1 R Ͻ gpH 1 R from 72 to 92% relative to histamine. The introduction of an additional methyl group in S-configuration (3S) and in R-configuration (3R) led to slight and large decreases in potency, respectively, compared with 2 at all four species isoforms. In addition, a decrease in efficacy in a range from approximately 34 to 56% for 3S and 3R compared with 2 at hH 1 R, bH 1 R, rH 1 R, and gpH 1 R was observed. The trifluoromethylated phenylhistamine 4 showed an increase in potency but a decrease in efficacy compared with 2 at all four species isoforms. The introduction of a methyl group in S-configuration 5S led to a slight decrease in potency compared with 4, but in case of R-configuration 5R, the decrease in potency was significant in the range of approximately 1 log unit compared with 4. The efficacy of the chiral trifluoromethylated phenylhistamines 5R and 5S were decreased significantly compared with 4 at hH 1 R, bH 1 R, and rH 1 R, but at gpH 1 R no decrease was observed. The exchange of the trifluoromethyl group against a bromine in compound 6 led to a slight increase in potency compared with 4. The efficacies of 6 compared with 4 were in the same range at hH 1 R and bH 1 R, but increased at rH 1 R and gpH 1 R. In general, the potencies of all small phenylhistamines 2-6 were more similar between Fig. 3 . Competition binding isotherms and concentration-response curves for the bulky bromine-substituted phenylhistamine 9 at hH 1 R, bH 1 R, rH 1 R, and gpH 1 R. The experiments were performed using Sf9 cell membranes expressing hH 1 R, bH 1 R, rH 1 R, or gpH 1 R and RGS4 as described under Materials and Methods. Data were analyzed by nonlinear regression and were best fit to one-site (monophasic) hH 1 R and bH 1 R on the one hand and between rH 1 R and gpH 1 R on the other hand, with higher potencies at rH 1 R and gpH 1 R.
All small phenylhistamines act as partial agonists at hH 1 R, bH 1 R, rH 1 R, and gpH 1 R. The introduction of a trifluoromethyl group or bromine in meta position of the terminal phenyl moiety increased affinity as well as potency at all four species isoforms. The introduction of an additional methyl group in ␣-position significantly reduced efficacy for both enantiomers. At all four species isoforms, the S-enantiomer showed higher affinity and potency than the R-enantiomer. Based on these results, it can be concluded that the phenylhistamines with the additional methyl group do not fit optimally into the binding pocket of the receptors and that the methyl group in R-configuration is more disfavored than the methyl group in S-configuration. Moreover, as shown by the decrease in efficacy this additional methyl group seems to hinder the activation process of the receptor independently of the configuration. The conformational change of the aromatic motif Phe 6.52 , Trp 6.48 , and Phe 6.44 (Straßer and Wittmann, 2007) probably cannot be fully established because of sterical hindrance.
The bulky phenylhistamines 7 to 9 were partial agonists at all four species isoforms. Compared with the corresponding phenylhistamines 2, 4, and 6, the potency was significantly higher at hH 1 R and bH 1 R, comparable at rH 1 R, but significantly lower at gpH 1 R. At all four species isoforms, the potency increased in the series 7 Ͻ 8 Ͻ 9. The highest potencies were found for the bromine-substituted phenylhistamine 9 (Fig. 3B ) in a pEC 50 range from 7 to 8, with a significant increase in potency in the series gpH 1 R Ͻ bH 1 R Ͻ hH 1 R Ϸ rH 1 R. The phenylhistamines 7 to 9 showed a significantly higher potency at hH 1 R that at gpH 1 R; thus, we have identified the first phenylhistamine derivatives with a higher potency at hH 1 R compared with gpH 1 R. The efficacies of 7 to 9 are comparable (approximately 90%) at hH 1 R, bH 1 R, and rH 1 R but significantly lower (approximately 70%) at gpH 1 R.
The dimeric phenylhistamines 10 and 11 were partial agonists with potencies in the range of approximately 5.5-6.5 at all four species isoforms. The potency as well as the efficacy of the trifluoromethylated derivative 11 was higher than the potency and efficacy of the unsubstituted and symmetrical dimeric phenylhistamine 10 at all four species isoforms.
Histaprodifen 12, the unsubstituted phenoprodifen 13, chiral phenoprodifens 14R and 14S, and dimeric histaprodifen 17 were analyzed in a previous study (Straßer et al., 2008a) . In this study, we completed the pharmacological characterization of the phenoprodifens, including the trifluoromethylated 15 and bromine-substituted phenoprodifen 16. In contrast to the chiral phenoprodifens 14R and 14S, the compounds 15 and 16 are partial agonists at all four species isoforms, as well as phenoprodifen 13 itself. The potency of 15 and 16 were in the same range as for 13 at hH 1 R and bH 1 R, but at rH 1 R and at gpH 1 R, an increase and a decrease in potency, respectively, were observed. Dimeric histaprodifen 17, acting as a partial agonist at all four species isoforms, exhibits potencies in the same range, as phenoprodifen 13.
Analysis of Phenylhistamines 7, 8, and 9 at hH 2 R-G s ␣ S in the Steady-State GTPase Assay. To determine whether 7, 8, and 9, showing selectivity for hH 1 R relative to gpH 1 R, also exhibit selectivity relative to the hH 2 R, we analyzed the compounds in the GTPase assay using the hH 2 R-G s ␣ S fusion protein. The potencies of phenylhistamines 7, 8, and 9 determined at hH 2 R-G s ␣ S showed a significant decrease of approximately 1 log unit compared with the potencies at hH 1 R (Table 3 ). As they were at hH 1 R, 7, 8, and 9 were partial agonists at hH 2 R-G s ␣ S . The efficacy of phenylhistamines 7 and 9 was significantly reduced at hH 2 R-G s ␣ S relative to hH 1 R, but for the trifluoromethyl-substituted phenylhistamine 8, there was no significant difference in efficacy between hH 1 R and hH 2 R-G s ␣ S . The imidazolylpropylguanidine (UR-AK57) 19 (Xie et al., 2006) acts as partial agonist at hH 1 R and hH 2 R-G s ␣ S , as well as the phenylhistamines 7, 8, TABLE 2 Potencies and efficacies of histamine, phenylhistamines, and phenoprodifens at hH 1 R, bH 1 R, rH 1 R, and gpH 1 R coexpressed with RGS4 in Sf9 cell membranes in the steady-state GTPase assay
All GTPase experiments were performed as described under Materials and Methods. Data were analyzed by nonlinear regression and were best fit to sigmoidal concentration-response curves. The efficacy (E max ) of histamine was set at 1.00. The E max values of all other compounds were referred to this value. Data shown are means Ϯ S.E.M. of at least three experiments were each performed in duplicate or triplicate. Membranes were used from independent membrane preparations. and 9. The potency of 19 is comparable with the potency of 7 at hH 1 R. But at hH 2 R-G s ␣ S , the potency of 19 is higher than that of 7, 8, and 9. Binding Mode of Phenoprodifen Based on Molecular Dynamics Simulations. In a previous study, we showed that suprahistaprodifen can bind to the H 1 R in two different orientations (Straßer et al., 2008a) . Likewise, the molecular dynamics simulations at hH 1 R and gpH 1 R led to stable ligand-receptor complexes for the phenoprodifens 13 to 16 in both orientations (Fig. 4, A and B, for 13) in the binding pocket. The positively charged amine moiety in the center of the phenoprodifens interacts electrostatically with the highly conserved, negatively charged Asp 3.32 and Tyr 7.43 (not shown in Fig. 4 to preserve clarity). In both orientations, one imidazole moiety forms stable hydrogen bonds to Ser 3.36 and Tyr 6.51 , the second imidazole moiety forms stable hydrogen bonds to a conserved Glu (Glu-181 in hH 1 R, Glu-190 in gpH 1 R) in the second extracellular loop and Trp 7.40 . These interactions are similar to those described for the dimeric histaprodifen in a prior study (Straßer et al., 2008b Fig. 4 for clarity) and Trp 6.48 . The highly conserved Trp 6.48 is involved in the rotamer toggle switch during the process of receptor activation (Crocker et al., 2006) . Our simulations reproducibly showed that Trp 6.48 was in a stable conformation parallel to the lipid bilayer, as described for the activate conformation of a GPCR (Straßer and Wittmann, 2007) , only for the phenoprodifens bound in orientation 2. In orientation 1, the planar conformation of Trp 6.48 was unstable in every simulation and switched back into an almost vertical conformation with regard to the lipid bilayer, but all other characteristics for the active state were conserved.
Compound
Prediction of the Orientation of Phenoprodifen 13. The predicted pK i values for phenoprodifen in orientations 1 and 2 are summarized in Fig. 2C and Table 4 , respectively. The data show that orientation 1 is clearly preferred at hH 1 R and bH 1 R, but at rH 1 R and gpH 1 R, neither orientation 1 nor orientation 2 is preferred. The calculated pK i value reflects the fact that phenoprodifen binds in both orientations. A comparison of the predicted pK i values (including orientations 1 and 2) with the experimental ones shows a very good correlation between prediction and experiment at all four species isoforms.
Interaction Energy of Phenoprodifen 13 with hH 1 R and gpH 1 R. In Fig. 5 , the interaction energy of phenoprodifen 13 in orientation 1 and orientation 2, respectively, with hH 1 R and gpH 1 R is calculated for 1 ns of simulation time during the equilibrated productive phase. The interaction energy of phenoprodifen 13 with hH 1 R (Fig. 5A) is significantly different (p Ͻ 0.025) between orientation 1 [⌬E(hH 1 R-13) ϭ Ϫ549 Ϯ 22 kJ/mol] and orientation 2 [⌬E(hH 1 R-13) ϭ Ϫ471 Ϯ 30 kJ/mol]. In contrast, the mean interaction energy between ligand and receptor is not significantly different at gpH 1 R (Fig. 5B) (Fig. 6A ) and 2 (Fig. 6B) , the bulky phenylhistamines are bound similarly to the phenylhistamine-histamine partial structure of the phenoprodifen in orientations 1 (Fig. 4A ) and 2 (Fig. 4B) . However, we observed a very high flexibility of the terminal histamine moiety in both orientations because the stabilization with the second diphenylpropyl moiety is lost. The third binding mode identified is very different from binding modes 1 and 2. Compared with binding mode 2, the whole ligand is shifted to the left in direction of transmembrane helix 5, with the following consequences. First, the hydrogen bond between the terminal histamine moiety and Ser 3.36 is broken. Second, a new hydrogen bond between the terminal histamine moiety and Lys 5.39 is formed in analogy to the binding mode described for histamine (Fig.  6C) . However, because of the high flexibility of the terminal histamine moiety, the hydrogen bond to Lys 5.39 was not observed during the entire simulation time. In binding mode 4, the terminal histamine moiety established a stacked aromatic interaction with Tyr 3.33 and to the hydroxyl moiety of Steady-state GTPase activity in Sf9 cell membranes expressing hH 1 R and RGS4 or hH 2 R-G s␣S was determined as described under Materials and Methods. Data were analyzed by nonlinear regression and were best fit to sigmoidal concentrationresponse curves. The efficacy (E max ) of histamine was set 1.00. The E max values of all other compounds were referred to this value. Data shown are means Ϯ S.E.M. of at least three experiments, each performed in duplicate. Membranes were used from independent membrane preparations. (Fig. 6D) . The bromine of phenylhistamine 9 is located near Ser 2.61 in gpH 1 R and Asn 2.61 in hH 1 R, respectively. However, there is a gap between the bromine and Ser 2.61 (Fig. 6E) , but a close contact between bromine and Asn 2.61 (Fig. 6F) . The distance between the bromine of 9 and Ser 2.61 in gpH 1 R is approximately 3.5 Å and between the bromine of 9 and Asn 2.61 in hH 1 R is approximately 2.6 Å. Thus, the van der Waals and electrostatic interaction between bromine and Asn 2.61 is more effective than between bromine and Ser 2.61 .
Discussion
Pharmacological Differences of Bulky Phenylhistamines and Phenoprodifens at hH 1 R, bH 1 R, rH 1 R, and gpH 1 R. It has been assumed that, as a general rule, synthetic agonists exhibit higher potency and efficacy at gpH 1 R than at hH 1 R Straßer et al., 2008a) . However, as a notable exception, the imidazolylpropylguanidine 19 (UR-AK57), originally designed as a selective H 2 R agonist, exhibits higher potency and efficacy as hH 1 R-agonist than as gpH 1 R-agonist (Xie et al., 2006) .
In this study, we analyzed 11 new phenylhistamines and phenoprodifens at four H 1 R species isoforms. Compared with the small phenylhistamines, the larger phenylhistamines 7, 8, and 9 exhibited a completely different pharmacological profile at hH 1 R, bH 1 R, rH 1 R, and gpH 1 R. The affinities and potencies of these compounds are, in general, higher at hH 1 R and rH 1 R compared with gpH 1 R, whereas bH 1 R shows values between those for hH 1 R and rH 1 R on the one hand and for gpH 1 R on the other hand. Thus, we have identified the first phenylhistamines with higher affinity at hH 1 R than at gpH 1 R. The differences pK i (hH 1 R)-pK i (gpH 1 R) or pEC 50 -(hH 1 R)-pEC 50 (gpH 1 R) are positive and significantly higher for the trifluoromethylated 8 or bromine-substituted 9 phenylhistamine than for the unsubstituted phenylhistamine 7. Molecular dynamics simulations revealed a very different binding mode of the phenylhistamines compared with that of the phenoprodifens. Compared with the histamine moiety of the phenoprodifen, the terminal histamine moiety of the phenylhistamine is shifted to the left near transmembrane helix 5. The hydrogen bond between the imidazole moiety and Ser 3.36 is lost. Instead, the imidazole moiety establishes a new hydrogen bond to Lys 5.39 (Fig. 6C) . Thus, the binding mode of this terminal histamine moiety is very similar to the binding mode described for histamine . The trifluoromethyl group or the bromine of 8 and 9, respectively, are in close contact to Asn 2.61 in the case of hH 1 R (Fig.  6F ) and to Ser 2.61 in the case of gpH 1 R (Fig. 6E) . Asn 2.61 is a selectivity switch between hH 1 R and gpH 1 R . Based on the simulation studies, it can be proposed that this amino acid difference between hH 1 R and gpH 1 R is important for the observed species differences. However, because the affinity and potency of 8 and 9 at bH 1 R (Asn 2.61 ) are different from those of hH 1 R (Asn 2.61 ) and rH 1 R (Asn 2.61 ) The experimental binding affinities of phenylhistamine 2, dimeric phenylhistamine 10, histaprodifen 12, and dimeric histaprodifen 17 were used to predict the binding affinities of phenoprodifen 13 in orientations 1 and 2 at hH 1 R, bH 1 R, rH 1 R, and gpH 1 R. Calculations were performed as described under Materials and Methods. on one hand and gpH 1 R (Ser 2.61 ) on the other hand, it is likely that in addition to the Asn 2.61 /Ser 2.61 mutation, other differences in amino acid sequences contribute to the pharmacological differences as well.
In contrast to the observations made for phenylhistamines, the introduction of a trifluoromethyl group or a bromine into the terminal phenyl moiety of the phenoprodifens did not increase affinity or potency. In a previous study (Straßer et al., 2008b) , we have described that the unsubstituted phenoprodifen can bind in two different orientations into the binding pocket of the H 1 R. In orientation 1, the histaprodifen partial structure is located near TM5, and the phenylhistamine partial structure near TM2. In orientation 2, the phenylhistamine partial structure is located near TM5 and the histaprodifen partial structure near TM2. Further molecular dynamics simulations have shown that the trifluoromethyl- Fig. 6 . Binding mode of bulky bromine-substituted phenylhistamine 9 at gpH 1 R and hH 1 R. Bromine-substituted phenylhistamine 9 in the binding pocket: A, binding mode 1 at gpH 1 R. B, binding mode 2 at gpH 1 R. C, binding mode 3 at gpH 1 R. D, binding mode 4 at gpH 1 R, representing the most stable conformation during MD simulation. E, most preferred binding mode of bromine-substituted phenylhistamine 9 in the binding pocket of gpH 1 R observed in MD simulations. F, most preferred binding mode of bromine-substituted phenylhistamine 9 in the binding pocket of hH 1 R observed in MD simulations. The MD-simulations were performed as described under Materials and Methods. A-D, hydrogen bonds and electrostatic interaction between ligand and amino acids are marked as red dashed lines; the black circle marks the free terminal imidazolyl moiety. D, the yellow arrow indicates a stacked aromatic interaction between the free terminal imidazolyl moiety of 9 and Tyr 3.33 . E and F, for the ligand, the electrostatic potential surface is shown; red indicates positive charge, green and brown indicates nearly neutral regions, blue indicates negative charge. The van der Waals surfaces of the most important amino acid side chains that are interacting with the ligand are given in gray shading. The black circles mark the contact between the bromine and Ser 2.61 and Asn 2.61 , respectively. (Table 2) at hH 1 R and gpH 1 R. Thus, it can be proposed that the binding of phenoprodifen shifts the equilibrium between the inactive and active states of the H 1 R toward the active state. The highly conserved Trp 6.48 is involved in a rotamer toggle switch during the process of receptor activation and shows a vertical orientation with respect to lipid bilayer in the inactive state (Fig.  4A) , but a parallel orientation in the active state (Fig. 4B ) of a GPCR (Crocker et al., 2006) . For orientation 1 of 13 (Fig.  4A) , the MD simulations showed a nearly vertical orientation of Trp 6.48 , reflecting the inactive state at hH 1 R as well as at gpH 1 R. In contrast, for orientation 2 (Fig. 4B) of 13, the MD simulation revealed a planar orientation of Trp 6.48 as proposed for the active state of a GPCR. Based on these results, it is suggested that phenoprodifens stabilize the inactive state in orientation 1 but the active state of H 1 R in orientation 2. Because orientation 1 is the preferred one at hH 1 R, whereas orientations 1 and 2 are established in comparable fractions at gpH 1 R, the reduced efficacy of 13 at hH 1 R compared with gpH 1 R can be explained.
Pharmacology of Small Chiral Phenylhistamines and Chiral Phenoprodifens. For the small phenylhistamines 3R and 3S, the S-enantiomer showed a significantly higher affinity and potency than the R-enantiomer at all four species isoforms. The introduction of the additional methyl group in 3R and 3S compared with phenylhistamine 2 led to a significant decrease in efficacy. However, the picture is different for the chiral phenoprodifens 14R and 14S. In this case, only at hH 1 R does the S-enantiomer possess the higher affinity; at bH 1 R, rH 1 R, and gpH 1 R, the R-enantiomer possesses higher affinity. As already mentioned, molecular dynamics simulations showed that the chiral phenoprodifens can bind in two different orientations in analogy to the two orientations of the unsubstituted phenoprodifen. Based on these experimental results, concerning affinity, it is suggested that at hH 1 R, the amount of orientation 2 of the chiral phenoprodifens is increased compared with the unsubstituted phenoprodifen 13. Besides that, the additional methyl group, proposed to be located in the same pockets as the analog methyl groups for 3R and 3S, led to a decrease in efficacy for 14R and 14S. 
Synthetic Agonists and H 1 -Receptor Isoforms 463
Pharmacology of Phenylhistamines 7, 8, and 9 and Imidazolylpropylguanidine 19 (UR-AK57) at hH 1 R and hH 2 R-G s ␣ S . A recent study (Xie et al., 2006) revealed that the imidazolylpropylguanidine 19 (UR-AK57; Fig. 1 ) acts as a partial agonist at hH 2 R-G s ␣ S , hH 1 R, and gpH 1 R. The potency of 19 at hH 2 R-G s ␣ S is significantly higher than at hH 1 R. In addition, the potency of 19 is decreased at gpH 1 R (pEC 50 , 6.12 Ϯ 0.06) compared with hH 1 R. Thus, 19 is the first synthetic agonist with higher potency at hH 1 R than at gpH 1 R. Our data show that phenylhistamines 8 and 9 possesses a significantly higher potency at hH 1 R compared with gpH 1 R, as is the case for 19. Thus, there are now three synthetic agonists with a higher potency at hH 1 R compared with gpH 1 R. In addition, the phenylhistamines 8 and 9 act as partial agonists at hH 2 R-G s ␣ S . Compound 19 shows higher potency at hH 2 R-G s ␣ S than at hH 1 R (Xie et al., 2006) . In contrast, phenylhistamines 8 and 9 show higher potency at hH 1 R than at hH 2 R-G s ␣ S . Thus, whereas 19 exhibits selectivity for hH 2 R compared with hH 1 R, the opposite is true for 8 and 9.
A comparison of imidazolylpropylguanidine 19 and phenylhistamines 8 and 9 at the level of ligand structure (Fig. 1 ) reveals differences, because imidazolylpropylguanidines and phenylhistamines represent different chemical classes, but also similarities. In particular, 19 as well as 8 and 9 possess free terminal imidazolyl moieties on the one hand, and an overlay of these ligands shows that they occupy similar volumes ( Fig. 7A) with similar surface properties, like electrostatic potential (Fig. 7B ). Most importantly, 19 possesses only one imidazole moiety. Thus, this compound can only bind in one possible orientation to the H 1 R, with the histamine moiety in region between TM5 and TM3 and with the 3-cyclohexylbutanoyl moiety close to TM2 (Fig. 7, C and D) , comparable with the binding modes 2 to 4 of 9 (Fig. 4, E and  F ). There is a gap between the cyclohexyl moiety of 19 and Ser 2.61 in gpH 1 R (Fig. 7C ) but a closer contact between the cyclohexyl moiety and Asn 2.61 in hH 1 R. Accordingly, the van der Waals interaction between cyclohexyl moiety and Asn 2.61 is more effective than between cyclohexyl moiety and Ser 2.61 , resulting in a higher potency at hH 1 R compared with gpH 1 R. Thus, it must be concluded that phenylhistamines 8 and 9 bind in modes 2-4, with the phenyl moiety located near TM2 of the H 1 R. However, because binding mode 4 is the most stable in MD simulations, binding mode 4 should be the preferred one.
Conclusions
Our studies reveal substantial pharmacological differences among human, bovine, rat, and guinea pig H 1 R species isoforms for different classes of agonists, such as phenylhistamines and phenoprodifens. Our studies also show that bH 1 R and rH 1 R can be classified as intermediate between hH 1 R and gpH 1 R, but hH 1 R is more similar to bH 1 R and rH 1 R is more similar to gpH 1 R. In the present study, we have identified the first phenylhistamines possessing a higher affinity and potency at hH 1 R than at gpH 1 R. Thus, we further corroborate the concept that it is possible to obtain selective H 1 R agonists with higher affinity for hH 1 R than for gpH 1 R. The advantage of the compounds studied herein compared with imidazolylpropylguanidines is that they possess higher selectivity relative to H 2 R.
